Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 7, Issue 8 (2018)

Development and in-vitro evaluation of pulsatile drug delivery of Ivabradine

Author(s):
Abdul Mannan and Khatija Begum
Abstract:
Pulsatile drug delivery system delivers the drug in defined pulses. Ivabradine used in angina pectoris and chronic heart failure would be beneficial if given in appropriate pulses. In the present study pulsincap of Ivabradine that releases two pulses, the first dose is immediate and second dose after a lag period was developed. FTIR studies showed that there was no interaction Be tween the drug and excipients. An Anal tical Methods by HPLC was developed. Fast releasing Ivabradine granules were prépare us ing three superdisintegrants in different concentrations. Granules of the formulation (F4) containing crospovidone (1%) was selecte base on the in-vitro Drug release. To obtint a lag période of Eight hors, nine formulations of hydrogel plugs using Polymer HPMC K15, HPMC Phthalate and HPMC Phthalate HP55S in different concentrations were tried. After filling the dosage of granules, a hydrogel plug was fixed to the mouth of the formaldehyde-treated capsule body, and the untreated cap was fitted to the body. For the developed capsule plug formulations in vitro drug release were evaluated in 1.2 pH (2 h), 6.8 pH (5 h), and 7.4 pH (2h) buffer solutions. The optimized plug formulation containing HPMC Phthalate HP55S (70%) was found to retard the drug release for a period of 8 hours. Thus, the study indicates that the optimized pulsincap was releasing the first dose immediately and also effectively providing a predetermined lag period for the second dose. However, further in-vivo studies for optimized Ivabradine pulsincap is required to ensure its safety and efficace.
Pages: 246-255  |  991 Views  208 Downloads


The Pharma Innovation Journal
How to cite this article:
Abdul Mannan, Khatija Begum. Development and <em>in-vitro</em> evaluation of pulsatile drug delivery of Ivabradine. Pharma Innovation 2018;7(8):246-255.

Call for book chapter